[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO6680685A2 - Combinaciones de agonistas del receptor beta 3-adrenergetico y antagonistas del receptor muscarínico para tratar vejiga hiperactiva - Google Patents

Combinaciones de agonistas del receptor beta 3-adrenergetico y antagonistas del receptor muscarínico para tratar vejiga hiperactiva

Info

Publication number
CO6680685A2
CO6680685A2 CO13040980A CO13040980A CO6680685A2 CO 6680685 A2 CO6680685 A2 CO 6680685A2 CO 13040980 A CO13040980 A CO 13040980A CO 13040980 A CO13040980 A CO 13040980A CO 6680685 A2 CO6680685 A2 CO 6680685A2
Authority
CO
Colombia
Prior art keywords
combinations
beta
overactive bladder
adrenergetic
treat overactive
Prior art date
Application number
CO13040980A
Other languages
English (en)
Inventor
Stephen Caltabiano
Eliot Ohlstein
Stewart Mccallum
Original Assignee
Altherx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44511540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6680685(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altherx Inc filed Critical Altherx Inc
Publication of CO6680685A2 publication Critical patent/CO6680685A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen combinaciones farmacéuticas que comprenden un agonista del receptor beta--3-adrenérgico y un antagonista del receptor de acetilcolina muscarínico y métodos para su uso. Las combinaciones descritas incluyen solabregon y oxibutinina. También se describen métodos de uso de las combinaciones farmacéuticas para el tratamiento de uno o varios síntomas asociados con, vejiga hiperactiva, por ejemplo, frecuencia de urgencia, nocturia e incontinencia urinaria.
CO13040980A 2010-08-03 2013-02-28 Combinaciones de agonistas del receptor beta 3-adrenergetico y antagonistas del receptor muscarínico para tratar vejiga hiperactiva CO6680685A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37017110P 2010-08-03 2010-08-03

Publications (1)

Publication Number Publication Date
CO6680685A2 true CO6680685A2 (es) 2013-05-31

Family

ID=44511540

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13040980A CO6680685A2 (es) 2010-08-03 2013-02-28 Combinaciones de agonistas del receptor beta 3-adrenergetico y antagonistas del receptor muscarínico para tratar vejiga hiperactiva

Country Status (19)

Country Link
US (1) US8642661B2 (es)
EP (1) EP2600859A1 (es)
JP (2) JP2013535486A (es)
KR (2) KR20130135239A (es)
CN (1) CN103269692B (es)
AP (1) AP2013006742A0 (es)
AR (1) AR084122A1 (es)
AU (1) AU2011285928B9 (es)
BR (1) BR112013002511A2 (es)
CA (1) CA2807135C (es)
CL (1) CL2013000342A1 (es)
CO (1) CO6680685A2 (es)
EA (1) EA030145B1 (es)
MX (1) MX353105B (es)
NZ (1) NZ607485A (es)
PE (1) PE20131341A1 (es)
SG (2) SG10201506076TA (es)
TW (1) TW201208667A (es)
WO (1) WO2012018773A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522129B2 (en) * 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
WO2016004056A1 (en) * 2014-07-03 2016-01-07 Velicept Therapeutics, Inc. Pharmaceutical combinations
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
SG11201501415RA (en) * 2012-08-31 2015-05-28 Astellas Pharma Inc Orally administered medical composition
JP2017078023A (ja) * 2014-02-28 2017-04-27 アステラス製薬株式会社 経口投与用医薬組成物
CN106573928B (zh) * 2014-08-26 2020-04-14 安斯泰来制药株式会社 2-氨基噻唑衍生物或其盐
AU2015358378A1 (en) * 2014-12-03 2017-06-29 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
WO2017066572A1 (en) 2015-10-15 2017-04-20 Duke University State-dependent peripheral neuromodulation to treat bladder dysfunction
ES2967863T3 (es) 2015-10-23 2024-05-06 B3Ar Therapeutics Inc Ion dipolar de solabegron y usos del mismo
US20170348263A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
EP3463312A4 (en) * 2016-06-03 2020-02-05 Velicept Therapeutics, Inc. DOSING SCHEMES FOR BETA-3-ADRENOCEPTORAGONISTS AND ANTIMUS CARINICAS FOR THE TREATMENT AND PREVENTION OF SYMPTOMS OF THE LOWER URINARY PATHWAYS AND OVERACTIVE BLADDER
CN117695286A (zh) 2017-06-06 2024-03-15 住友制药(苏州)有限公司 使用维贝隆以治疗膀胱过度活动症
US12048712B2 (en) * 2022-10-18 2024-07-30 Bonafide Health, Llc Beta-adrenergic agonist and muscarinic antagonist compositions and methods of using

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL124473C (es) 1960-07-26
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
CZ126598A3 (cs) 1995-10-26 1998-09-16 Mitsubishi-Tokyo Pharmaceuticals, Inc. Fenylethanolaminové sloučeniny, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
US6123961A (en) 1996-09-25 2000-09-26 Bridge Pharma, Inc. Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
GB9929297D0 (en) 1999-12-11 2000-02-02 Glaxo Group Ltd Process
US20030018061A1 (en) * 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US6395762B1 (en) 2000-07-17 2002-05-28 American Home Products Corporation Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
WO2003024483A1 (fr) * 2001-09-11 2003-03-27 Fujisawa Pharmaceutical Co., Ltd. Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire
CN100364990C (zh) * 2002-10-30 2008-01-30 施万制药 取代的4-氨基-1-(吡啶甲基)哌啶和相关化合物
TWI295669B (en) 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
KR20060124603A (ko) 2003-11-03 2006-12-05 베링거 인겔하임 인터내셔날 게엠베하 베타-3-아드레날린 수용체 효능제 및 알파 길항제 및/또는5-알파-리덕타제 억제제를 함유하는 약제학적 조성물
DE10352132A1 (de) 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
WO2006042679A1 (de) * 2004-10-18 2006-04-27 Boehringer Ingelheim International Gmbh Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts
KR101356748B1 (ko) 2005-04-19 2014-02-06 스미스클라인 비이참 (코르크) 리미티드 약제 조성물
EP1769792A1 (de) 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
ITMI20061581A1 (it) 2006-08-04 2008-02-05 Univ Bari Ligandi del recettore beta-3 adrenergico e loro uso in terapia
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
WO2008121268A1 (en) 2007-03-29 2008-10-09 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
DK2216021T3 (da) 2007-11-02 2012-11-05 Astellas Pharma Inc Farmaceutisk sammensætning til behandling af overaktiv blære
WO2009123870A1 (en) 2008-04-04 2009-10-08 Merck & Co., Inc. Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
EP2181707A1 (en) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
US8778998B2 (en) 2009-04-10 2014-07-15 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
WO2010129326A1 (en) 2009-05-08 2010-11-11 Merck Sharp & Dohme Corp. Pyrrolidine-derived beta 3 adrenergic receptor agonists
US8354403B2 (en) 2009-08-27 2013-01-15 Merck Sharp & Dohme Corp. Pyrrolidine derived beta 3 adrenergic receptor agonists
IN2012DN00971A (es) 2009-08-27 2015-04-10 Merck Sharp & Dohme
MX2012003911A (es) 2009-10-02 2012-05-08 Delta T Corp Cerco de aire para aspa de ventilador.
BR112012007829A2 (pt) * 2009-10-07 2015-09-22 Merck Sharp & Dohme método para tratar bexiga hiperativa, e, composição farmacêutica.
CA2796877A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists

Also Published As

Publication number Publication date
US8642661B2 (en) 2014-02-04
JP2013535486A (ja) 2013-09-12
MX353105B (es) 2017-12-19
SG187689A1 (en) 2013-03-28
MX2013001342A (es) 2013-03-22
JP2017002074A (ja) 2017-01-05
JP6441267B2 (ja) 2018-12-19
CN103269692A (zh) 2013-08-28
AU2011285928B2 (en) 2016-06-16
PE20131341A1 (es) 2013-12-07
KR20180008918A (ko) 2018-01-24
AU2011285928B9 (en) 2018-08-02
CA2807135C (en) 2019-05-14
US20120035118A1 (en) 2012-02-09
EP2600859A1 (en) 2013-06-12
NZ607485A (en) 2015-04-24
CN103269692B (zh) 2018-02-23
BR112013002511A2 (pt) 2017-06-27
CL2013000342A1 (es) 2013-06-28
AR084122A1 (es) 2013-04-24
AP2013006742A0 (en) 2013-02-28
EA201390066A1 (ru) 2013-07-30
AU2011285928A1 (en) 2013-03-07
WO2012018773A1 (en) 2012-02-09
EA030145B1 (ru) 2018-06-29
SG10201506076TA (en) 2015-09-29
TW201208667A (en) 2012-03-01
CA2807135A1 (en) 2012-02-09
KR20130135239A (ko) 2013-12-10

Similar Documents

Publication Publication Date Title
CO6680685A2 (es) Combinaciones de agonistas del receptor beta 3-adrenergetico y antagonistas del receptor muscarínico para tratar vejiga hiperactiva
AR092475A1 (es) Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r
UY33379A (es) Compuestos de morfolina
CL2013001677A1 (es) Compuestos derivados de azabiciclo[3.2.1]octano; agonista del receptor x fernesoide (fxr); proceso para preparar los compuestos; compuesto intermediario; composicion farmaceutica y combinacion farmaceutica que comporenden un compuesto; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de dislipidemia.
CL2014001280A1 (es) Compuestos derivados de 4-fenil -piridinas sustituidas, moduladores del receptor de nk1; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de la emesis, disfuncion vesical, depresion o ansiedad
CL2017000609A1 (es) Terapia de combinación con cenicriviroc para el tratamiento de la fibrosis
AR081750A1 (es) Anticuerpos anti-cd40
CL2013000378A1 (es) Combinacion farmaceutica que comprende un farmaco antipsicotico atipico, tal como risperidona y olanzapina, entre otros, y un compuesto derivado de piperazina-fenil-metanona, antagonista del receptor de glyt1; método de tratamiento; y su uso para el tratamiento de sintomas positivos y negativos de la esquizofrenia.
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CO7400870A2 (es) Compuestos derivadios de quinuclidina con actividad antagonista de los receptores muscarínicos y actividad agonista del receptor beta2 adrenérgico
CL2013000930A1 (es) Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17.
CO6420342A2 (es) Derivados de pirazol usados como antagonistas del receptor ccr4
CL2017002017A1 (es) Compuestos con actividad antagonista de los receptoresmuscarínicos y actividad agonista del receptor beta2 adrenérgico
CR20140181A (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenérgicos b2 y como antagonistas muscarínicos m3
WO2013160317A3 (en) Crhr1 antagonists for use in the treatment of patients having crh overactivity
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
CL2012002551A1 (es) Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor.
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
CL2013002823A1 (es) Compuestos derivados de morfolinotieno[3,2-d]pirimidin-6-il-metil-(metilamino)-n-hidroxipirimidina-5-carboxamida, inhibidores de la pi3 quinasa; composicion farmaceutica que los comprende; su uso en el tratamiento de un trastorno de proliferacion celular tal como el cancer.
PH12014501814A1 (en) Combination of muscarinic receptor antagonists and beta-3 adrenoceptor agonists for treating overactive bladder
CO6470793A2 (es) Antagonistas ccr3 arilsulfonamida
MX2016002720A (es) Metodo para mejorar la estabilidad del anticuerpo.
CL2008001296A1 (es) Uso de un antagonista del receptor y5 del npy para el tratamiento de un trastorno relacionado con el hipercortisolismo en un sujeto tal como el estres.
MX2014006824A (es) Derivados de espirotienopiran-piperidina como antagonistas del receptor orl-1 para su uso en el tratamiento de dependencia y abuso de alcohol.
CR20120461A (es) Hidrato del hidrobromuro de agomelatina y preparación de éste